Literature DB >> 30071178

Pharmacological management of hyponatremia.

Theodosios Filippatos1, Moses Elisaf2, George Liamis2.   

Abstract

INTRODUCTION: Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. Furthermore, it is associated with increased morbidity and mortality. AREAS COVERED: This review discusses the efficacy and side effects of the currently available treatment options for hyponatremia and the differences in the pharmacological approach between the European and USA guidelines. Additionally, the authors provide their expert perspectives on current treatment strategies and what they expect from this field in the future. EXPERT OPINION: Several pharmacological options are available for the treatment of hyponatremia, but data from trials examining and comparing these treatments are missing. Regarding chronic hyponatremia, the role of vaptans should be further analyzed, focusing on comparisons with other active treatments on patient-relevant outcomes and not only on serum sodium concentration. Clinicians should be cautious to an overly rapid increase in serum sodium levels with all available treatment strategies. Finally, it is important to ascertain whether correction of serum sodium levels improves mortality in hyponatremic patients.

Entities:  

Keywords:  Hyponatremia; demeclocycline; loop diuretics; saline; urea; vaptans

Mesh:

Year:  2018        PMID: 30071178     DOI: 10.1080/14656566.2018.1504920

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  1 in total

1.  Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.

Authors:  Yukyung Kim; Nari Lee; Kyung Eun Lee; Hye Sun Gwak
Journal:  Eur J Clin Pharmacol       Date:  2020-02-13       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.